IRIS
MIGLINO, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.997
AS - Asia 1.350
NA - Nord America 589
SA - Sud America 118
AF - Africa 23
OC - Oceania 4
Totale 15.081
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 12.737
SG - Singapore 588
US - Stati Uniti d'America 542
CN - Cina 366
VN - Vietnam 230
FR - Francia 102
BR - Brasile 77
HK - Hong Kong 46
FI - Finlandia 32
DE - Germania 25
GB - Regno Unito 25
AR - Argentina 21
JP - Giappone 20
MX - Messico 20
CA - Canada 16
BD - Bangladesh 15
IQ - Iraq 14
IN - India 13
CH - Svizzera 11
PH - Filippine 11
NL - Olanda 10
ID - Indonesia 8
TR - Turchia 7
UA - Ucraina 7
IE - Irlanda 6
RU - Federazione Russa 5
VE - Venezuela 5
AU - Australia 4
DZ - Algeria 4
EC - Ecuador 4
ES - Italia 4
PK - Pakistan 4
TH - Thailandia 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AZ - Azerbaigian 3
CO - Colombia 3
GR - Grecia 3
PY - Paraguay 3
SI - Slovenia 3
BE - Belgio 2
CL - Cile 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
IR - Iran 2
KE - Kenya 2
LT - Lituania 2
MA - Marocco 2
MG - Madagascar 2
PE - Perù 2
PL - Polonia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SE - Svezia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
TZ - Tanzania 2
UZ - Uzbekistan 2
AO - Angola 1
AT - Austria 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
BS - Bahamas 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
NI - Nicaragua 1
NO - Norvegia 1
PS - Palestinian Territory 1
QA - Qatar 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 15.081
Salva come PNG Salva come JPEG
Città #
Genova 6.720
Genoa 3.826
Rapallo 1.216
Vado Ligure 827
Singapore 275
San Jose 225
Lauterbourg 91
Ashburn 78
Ho Chi Minh City 70
Beijing 54
Hanoi 48
Hong Kong 45
New York 39
Council Bluffs 34
Helsinki 32
Bordighera 31
Milan 30
Frankfurt am Main 23
Tokyo 17
Santa Clara 15
Mexico City 13
Valenza 12
Zurich 11
Da Nang 9
Los Angeles 9
Rome 9
Montreal 8
Tianjin 8
Amsterdam 7
Cardiff 7
Orem 7
São Paulo 7
Biên Hòa 6
Dublin 6
Hải Dương 6
Ninh Bình 6
Paris 6
Toronto 6
Baghdad 5
Buffalo 5
Haiphong 5
Atlanta 4
Bắc Ninh 4
Can Tho 4
City of London 4
Denver 4
Dhaka 4
Istanbul 4
Johannesburg 4
London 4
Rovereto 4
Sydney 4
Abu Dhabi 3
Baku 3
Brooklyn 3
Buenos Aires 3
Chennai 3
Corrientes 3
Guangzhou 3
Ljubljana 3
Madrid 3
Manchester 3
Marseille 3
Mumbai 3
Perugia 3
Phủ Lý 3
Shanghai 3
Addis Ababa 2
Algiers 2
Ankara 2
Antananarivo 2
Athens 2
Bandung 2
Basingstoke 2
Belgrade 2
Belo Horizonte 2
Curitiba 2
Dar es Salaam 2
Des Moines 2
Djursholm 2
Hat Yai 2
Lấp Vò 2
Macapá 2
Maracaibo 2
Miami 2
Nairobi 2
Naples 2
Nha Trang 2
Quito 2
Quận Ba 2
Rio de Janeiro 2
Salvador 2
San Juan 2
Schiavon 2
Ternopil 2
Tirana 2
Trieste 2
Turin 2
Tây Ninh 2
Vinh 2
Totale 14.009
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 240
A novel Bim-BH3-derived Bcl-X(L) inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity 220
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 220
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 218
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 211
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 209
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 208
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 203
Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: A translational18F-FDG PET/CT observation 200
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 197
Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission. 197
A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies 195
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 195
Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration 194
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 194
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 192
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 189
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 187
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 180
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 179
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 178
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. 176
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 176
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 170
An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline 170
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 170
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 169
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 169
Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome. 169
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 166
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 166
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 165
Molecular analysis of clonality in plasma cell dyscrasias. 164
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 164
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 163
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 162
Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia 162
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 159
Thalidomide in agnogenic and secondary myelofibrosis 156
Molecular analysis of the bcr rearrangement in a case of Ph'-negative blastic crisis of Ph'-positive chronic myelogenous leukemia. 156
Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: A Possible Role for RANK/RANKL Pathway 155
Bound and unbound pyridine dinucleotides in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. 153
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease 151
Clonal B lymphocytes lack bcr rearrangement in Ph-positive chronic myelogenous leukaemia. 151
Hepatosplenic T-cell lymphoma with aberrant expression of serum β-HCG: A case report 151
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles: Long-term results of the GITIL/FIL HD 0607 trial 150
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 148
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 148
An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma. 146
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 146
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 146
Epigenetic Regulation in Myelodysplastic Syndrome as A Consequence of A MicroRNA Dysregulation 144
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 143
Polyclonal pattern of X-inactivation in multiple myeloma. 143
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies 143
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 142
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia 141
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 140
Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. 139
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. 139
Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11 139
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. 137
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 137
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 137
Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines 135
Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. 134
Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia 134
Impact of hematological malignancies in patients undergoing cardiac surgery 134
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. 132
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 131
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 130
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 129
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. 128
A new glucose-6-phosphate dehydrogenase variant with congenital nonspherocytic hemolytic anemia (G6PD Genova). Biochemical characterization and mosaicism expression in the heterozygote. 127
Clonal analysis of hematologic malignancies using Mediterranean G6PD mosaicism. 124
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 123
Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin’s lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation 121
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. 115
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. 114
FRONT-LINE TREATMENT OF PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA WITH IMATINIB AND INTERFERON-ALPHA: 5-YEAR OUTCOME. 112
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 111
Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department 108
Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing and allogeneic bone marrow transplant 107
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. 107
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 106
Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with Imatinib mesylate. 104
Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. 103
Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement. 102
Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features 101
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa 100
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 99
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. 98
Vdelta1 T lymhocites from B-CLL patients recognize ULPB3 expressed on leukemic B cells and up-regulated by trans-retinoic acid 96
Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method. 90
Leucemia mieloide acuta Profilo genetico 89
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 88
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis 87
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? 87
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly. 84
Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases. 81
Totale 14.798
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.184
article - articoli 45.987
book - libri 0
conference - conferenze 403
curatela - curatele 0
other - altro 487
patent - brevetti 0
selected - selezionate 0
volume - volumi 307
Totale 94.368
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021260 0 0 0 0 0 0 0 0 0 96 61 103
2021/20221.206 34 77 87 140 48 85 74 249 67 111 54 180
2022/20231.456 133 122 34 167 246 246 4 102 210 26 146 20
2023/2024908 48 81 23 110 74 208 68 112 30 20 42 92
2024/20252.360 64 163 70 158 234 231 267 434 79 98 285 277
2025/20263.679 534 165 323 347 511 342 660 154 305 338 0 0
Totale 15.282